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Abstract Sphingomyelin plays complex structural and signal-
ing functions in the plasma membrane. Of special interest is that
hydrolysis of sphingomyelin to ceramide can modulate dynamics
of membrane rafts, which serve as signaling platforms for var-
ious receptors. This review is focused on a recently discovered
sphingomyelin-binding protein, lysenin, which can be used as a
unique probe to trace distribution and turnover of sphingomyelin
in cellular membranes. We analyze the primary and secondary
structures of lysenin with respect to its interaction with the
plasma membrane. The speci¢city of lysenin binding to sphin-
gomyelin, revealed by both biochemical and cytochemical ap-
proaches, is discussed.
" 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
For a long time lipids have been considered only as struc-
tural building elements of the plasma membrane. Recently,
however, several membrane lipids have been recognized as
precursors of bioactive molecules generated in cells after stim-
ulation of a number of cell surface receptors and functioning
as secondary messengers.
To follow individual plasma membrane lipids in vivo di¡er-
ent peptide and proteinaous probes have been established.
These probes interact speci¢cally with target lipids and thus
can serve as tools for monitoring the level of selected lipids at
activation of signaling pathways in cells. Until now the probes
for phosphatidylethanolamine [1], phosphatidylcholine [2],
phosphatidylserine [3,4], various phosphatidylinositols [5,6]
and cholesterol [7,8] have been developed. Recently, a new
unique protein, lysenin, which selectively recognizes sphingo-
myelin was isolated and cloned [9,10].
Sphingomyelin, a phosphosphingolipid, is an important
structural and functional constituent of cellular membranes.
Up to 50% of the total sphingomyelin amount in cells is
located in the plasma membrane, being concentrated in the
outer lea£et of the membrane [11,12]. Together with glyco-
sphingolipids and cholesterol, sphingomyelin is compartmen-
talized in specialized microdomains of the plasma membrane,
known as lipid rafts and caveolae [13,14]. Rafts are separated
from glycerophospholipid-rich environment in the plane of
the plasma membrane due to tight packing of saturated fatty
acyl chains of sphingolipids. The spaces between long acyl
chains of sphingolipids are ¢lled by cholesterol. The sphingo-
lipid/cholesterol-enriched rafts acquire the liquid-ordered
phase that displays low elasticity but allows di¡usion of dis-
tinct set of proteins in and out of these membrane structures
[15]. Because many of raft constituents, including sphingo-
myelin, are involved in cell signaling, the domains are likely
to serve as signaling platforms, particularly for immunorecep-
tors. A critical role for sphingomyelin in signal transduction is
manifested through the so-called sphingomyelin cycle [16], in
which sphingomyelinases are activated by a number of extra-
cellular agents such as 1K,25-dihydroxyvitamin D3, tumor
necrosis factor K, Q-interferon, interleukin-1 and arachidonate
[17^19]. Membrane sphingomyelin is hydrolyzed by activated
sphingomyelinases, which results in production of ceramide
serving, in turn, as a second messenger [16,20]. On the other
hand, conversion of sphingomyelin into ceramide leads to
changes in the physico-chemical properties of the plasma
membrane having possible physiological implications. To
this end, a tendency of ceramide to self-aggregate is thought
to facilitate coalescence of microdomains, a prerequisite phe-
nomenon for signal generation by raft-interacting receptors
[21,22]. Accordingly, it was found that activation of acid
sphingomyelinase in the plasma membrane and ceramide gen-
eration were essential for clustering of CD95 and CD40 re-
ceptors and triggering downstream apoptotic signals [23,24].
These ceramide functions may be determined rather by
changes in topology of its formation in the plasma membrane
(outer or inner lea£et) rather than ceramide action as a second
messenger [21]. In a line with this supposition was ¢nding that
generation of ceramide in either the outer or the inner lea£et
of liposomes induced endocytosis or blebbing of the mem-
brane, respectively [25]. Aside from the plasma membrane
pool of sphingomyelin, its mitochondrial pool was recently
implicated in a cell death promotion [26]. Therefore, identi¢-
cation of sphingomyelin pools and their membrane localiza-
tion are very important for understanding the putative speci-
alized sphingomyelin signaling pathways [21,27].
Compartmentalization of sphingomyelin in plasma mem-
brane rafts plays an essential role in pathogenesis of Creutz-
feldt^Jakob disease [28]. As prion, human immunode¢ciency
virus (HIV)-1 and Alzheimer proteins possess a common
sphingolipid-binding motif, membrane rafts are likely to be
involved in development of corresponding diseases [29]. Re-
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cently discovered sphingomyelinase activity associated with
low density protein implies that plasma membrane sphingo-
myelin could provide a non-receptor-based gate for the entry
of low density lipoprotein (LDL) cholesterol and could also
participate in the pathophysiology of atherosclerosis [30]. Fi-
nally, Niemann^Pick disease type A caused by de¢ciency of
acid sphingomyelinase extents the list of sphingomyelin-re-
lated diseases. Despite sphingomyelin involvement in physiol-
ogy and pathophysiology of cells, little is known about the
topological distribution of sphingomyelin and its dynamics in
a variety of cellular processes. The discovery of lysenin, a
novel sphingomyelin-speci¢c binding protein will facilitate
these studies.
2. Primary and secondary structure of lysenin and
lysenin-related proteins
Lysenin was isolated from the coelomic £uid of the earth-
worm Eisenia foetida as a protein that caused contraction of
rat vascular smooth muscles [9]. Lysenin polypeptide chain is
297 amino acids long with a calculated molecular mass of
33 440 Da, which is in good agreement with the results of
size-exclusion chromatography (33 000 Da) and much less
than that measured by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) (41 000 Da) [9,10]. This dis-
crepancy could be explained by glycosylation rather than by a
high content of acidic residues in lysenin because it only
slightly exceeds the average charge value.
Together with two additional proteins presented in coelo-
mic £uid and referred to as lysenin-related proteins, lysenin
comprises a family of proteins sharing sequences of high ho-
mology which are completely di¡erent from known sequences
of others proteins available in protein databanks. As shown in
Fig. 1A, the lysenin-related proteins have 72% or more of
amino acid residues identical to lysenin, about 17% of
strongly similar and only about 5% of residues di¡erent
from lysenin. Di¡erent residues are statistically distributed
along the entire polypeptide chain except positions 4^7 where
di¡erent residues are accumulated. In this region lysenin has a
two-residue deletion gap as compared to both lysenin-related
proteins (see Fig. 1A).
Sometimes lysenin-related protein 2 is called fetidin [31^33]
Fig. 1. The primary and secondary structure of lysenin. A: The sequence alignment of the lysenin family. The protein names are given on the
left, while the entry names of the TrEMBL sequence databases are listed on the right of the alignment. The residues are colored according to
the CLUSTAL X protein scheme [56]. In general, if one-letter code of amino acid residue is given on color background it means that it is the
same residue as in two other proteins or replacement is strongly similar, otherwise the residue code is given in appropriate color on white back-
ground. B: Prediction of the secondary structure elements of the lysenin chain. The solid line denotes the probability of L-strand and the
dashed line of helix. Proposed structured segments are marked on the top of the ¢gure.
FEBS 27172 22-4-03 Cyaan Magenta Geel Zwart
A.-B.A. Shakor et al./FEBS Letters 542 (2003) 1^62
or hemolysin (gbMsAAB67727.1); according to the TrEMBL
protein sequence database (entrysO18425), it is the product
of EFL3 gene and is the same protein, which in E. foetida cells
could be modi¢ed by di¡erent saccharide components. Ac-
cording to PROSITE motif search [34], the N-glycosylation
site for lysenin and lysenin-related protein 2 has been pre-
dicted at N248 and N250 residues, respectively (Table 1),
which is in agreement with experimental observations [31].
For lysenin-related protein 1, two N-glycosylation sites at
N33 and N151 residues have been predicted. All members
of the lysenin family possess a possible N-myristoylation
site, which could facilitate the anchoring of the proteins in
cell membranes.
All three proteins have several potential phosphorylation
sites speci¢c for protein kinase C, casein kinase II and tyro-
sine kinases (Table 1); the lysenin-related protein 1 has one
additional site speci¢c for cAMP- and cGMP-dependent pro-
tein kinases. The proteins of this family have a heme-ligand
signature and possess a weak homology with pyridoxamine
5P-phosphate oxidases (Table 1). Lysenin and lysenin-related
protein 1 are homologous with a part of the HypA domain
(hydrogenase nickel incorporation protein domain); lysenin
has an additional homology with a part of the cellulose-bind-
ing domain (CBM-2).
The secondary structure of lysenin has been predicted by us
using several recent methods available on the NPS@ server
(http://pbil.ibcp.fr) [35], by ALB algorithm [36] and by the
PHD method based on the neuronal network [37]. The aver-
age results of secondary structure prediction with the proba-
bility of the structure in question are presented on Fig. 1B.
More than half of the residues of the lysenin chain (53%) tend
to form L structures and 23% form turns and loops, while
helices are formed only by 6% of residues composing two
helical segments. The ¢rst one (shorter and with low proba-
bility) covers I145^T150 residues, while the second helix (with
high probability) is located close to the C-terminus (G256^
T267) of the lysenin chain. Each of the three proteins has 150^
160 of exposed residues and this is more than the expected
number (126) of exposed residues for a protein of the same
molecular mass, so they could form ellipsoidal globules.
All these proteins have two cysteine residues: C272, C283
(C274, C285 in lysine-related proteins) with di¡erent potential
ability of forming a disul¢de bond. The ¢rst residue C272
(C274) has a high probability (over 0.80) of forming a disul-
¢de bond while the second residue C283 (C285) has almost
the same probability of staying in the SH form. This may
suggest a tendency of these proteins to form dimers.
Lysenin has been classi¢ed as a membrane transport protein
by the Nomenclature Committee of the International Union
of Biochemistry and Molecular Biology (NC-IUBMB) (http://
www.chem.qmul.ac.uk/iubmb/mtp/). Recommended on the
mentioned website, WHAT software [38] based on analyses
of hydropathy and amphipathicity predicted in lysenin a
transmembrane helix located between residues V148 and
G164. In the case of both lysenin-related proteins, the pre-
dicted transmembrane helices were located between residues
Y131 and I147. This shift in the location of the transmem-
brane helix is unexpected, since the di¡erence between the
sequences of lysenin-related proteins 1 and 2 in region
Y131^I147 seems to be essential and more distinct than the
di¡erence between these sequences in lysenin-related protein 2
and lysenin. On the contrary, the sequence of the transmem-
brane helix suggested for lysenin only, V148^G164, looks sim-
ilar in all three proteins (for details see Fig. 1A). Moreover,
the subroutine of the WHAT program designed for protein
secondary structure prediction did not reveal any helical seg-
ments in any region of lysenin molecule, but indicated two
helical segments in the lysenin-related protein 2 chain, both
shifted to its C-terminus. The discrepancy between results of
analysis of hydropathy and amphipathicity and helical seg-
ments predicted by all the methods indicates that lysenin
and lysenin-related proteins have no helices capable of form-
ing a transmembrane domain. Taking into account a strong
lytic activity of lysenin, a possibility of an involvement of
other lysenin segments in the penetration of the plasma mem-
brane remains open.
3. Lysenin speci¢cally binds to sphingomyelin
There is a substantial body of evidence that lysenin binds
speci¢cally to sphingomyelin in the plasma membrane of
various cells and may therefore be used as a probe to study
distribution and function of sphingomyelin in cellular mem-
branes. Aside from sphingomyelin, lysenin isolated from
E. foetida does not bind to any other sphingolipid nor to
ceramide, sphingosine, sphingosine-1-phosphate, sphingosyl-
phosphorylcholine or galactosylceramide, as shown by immu-
nosorbent assay, thin layer chromatography immunostaining
and liposome lysis assay. These studies indicated also that
lysenin recognizes a precise molecular structure of sphingo-
Table 1
PROSITE and PFAM motifs and sites for lysenin family proteins
Motifs and sites Residue numbersa
Lysenin LRP-1 LRP-2
N-Glycosylation site 248 33; 151 250
N-Myristoylation site 61; 140 142 6; 63; 142
Protein kinase C phosphorylation site 2; 110; 150; 183 65; 185; 262 2; 112; 185
Casein kinase II phosphorylation site 32; 65; 82; 89; 219 93; 127; 146 34; 67; 84; 91; 221
Tyrosine kinase phosphorylation site 171 173 173
cAMP- and cGMP-dependent protein kinase
phosphorylation site
^ 113 ^
Peroxidases proximal heme-ligand signature 50ETRTVTATHSI60 52ETKTLTATHTL62 52ETKTLTASHSI62
Homology with (hydrogenase nickel incorporation
protein) HypA domain
63^78 69^80 ^
Homology with cellulose-binding domain 12^86 ^ ^
aAccording to multiple sequence alignment lysenin has deletion at positions 6, 7 and 300 as compared to two other members of the lysenin
family.
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myelin. Within the sphingomyelin molecule, lysenin required
the phosphorylcholine, sphingosine and fatty acid moieties for
binding [39]. We established that recombinant His-tagged ly-
senin recognizes sphingomyelin with the same speci¢city (Fig.
2). Incorporation of cholesterol into sphingomyelin-based syn-
thetic membrane signi¢cantly increased the total amount of
lysenin bound to the membrane. Surface plasmon resonance
revealed that cholesterol incorporation did not change the
kinetic parameters of the lysenin^sphingomyelin interaction,
suggesting that cholesterol incorporation may change the
topological distribution of sphingomyelin in the membrane,
thereby increasing the accessibility of sphingomyelin to lyse-
nin [39].
Owing to the sphingomyelin-speci¢c binding, lysenin was
applied as a cytochemical probe to visualize the phospholipid
on the surface of oligodendrocyte lineage cells [40]. The im-
munocytochemical studies showed that during cell develop-
ment, the content of sphingomyelin increased, although the
amount and distribution of cholesterol remained unchanged.
This kind of studies may clarify the role of sphingomyelin in
oligodendrocyte di¡erentiation, shedding light on the demye-
lination and remyelination in the brain. Lysenin was also used
for immuno£uorescent staining of ¢broblasts derived from a
patient with Niemann^Pick disease type A and permitted to
visualize two distinct pools of sphingomyelin in these cells
[39]. The disease is accompanied by an up to 50-fold increase
of cellular sphingomyelin level caused by de¢ciency of lyso-
somal acid sphingomyelinase. Despite this, immuno£uores-
cence staining of sphingomyelin on the surface of Niemann^
Pick patient-derived ¢broblasts was uniform and resembled
the staining pattern of normal ¢broblasts. After cell permea-
bilization, however, lysenin revealed a high level of sphingo-
myelin in lysosomes of Niemann^Pick ¢broblasts, which was
absent in normal cells [39]. These observations pointed to
lysenin as a potential probe for detection of sphingomyelin
in various cellular membranes under both normal and patho-
logical (e.g. lipid storage diseases) conditions. Interaction of
lysenin with sphingomyelin was in£uenced neither by sugar
and protein molecules of the cell surface nor by ¢xation meth-
ods (2^4% paraformaldehyde, 10 mM sodium periodate/form-
aldehyde), but the lysenin/sphingomyelin interaction was abol-
ished when the cells were ¢xed and permeabilized with alcohol
[40].
When applied onto living cells, lysenin exhibits a strong
cytotoxic and cytolytic activity directly related to the sphin-
gomyelin content in the plasma membrane of the cells. Sheep
erythrocytes, in which the sphingomyelin content is up to 51%
of total membrane phospholipids, were much more sensitive
to the lytic activity of lysenin than human and rat erythro-
cytes poorer in sphingomyelin (25% and 13% of total mem-
brane phospholipids, respectively). Preincubation of lysenin
with liposomes containing sphingomyelin, but not other phos-
pholipids, inhibited lysenin-induced hemolysis completely and
also abolished lysenin immunodetection in erythrocytes.
Moreover, treatment of erythrocyte membrane with sphingo-
myelinase abolished the ability of lysenin to induce hemolysis
[39]. By analogy to erythrocytes, the harmful e¡ect of lysenin
toward spermatozoa was correlated with sphingomyelin con-
tent in these cells, being higher in mouse than in frog sperma-
tozoa [41]. A detailed phylogenetic study performed by Ko-
bayashi et al. [42] indicated that sphingomyelin-containing
spermatozoa of vertebrates were damaged by lysenin. On
the contrary, spermatozoa of the vast majority of inverte-
brates were insensitive to lysenin treatment and this correlated
with a lack of detectable sphingomyelin level in these cells.
The molecular mechanism of membrane damage caused by
lysenin is not elucidated, although it does not follow sphingo-
myelinase action [39]. The presence of lysenin sequence able to
form a transmembrane domain is in question, therefore the
protein may attach to the membrane surface without penetra-
tion of the membrane bilayer. Subsequently, hydrophobic do-
mains of lysenin could cause a local distortion of the lipid
bilayer. In addition, an assembly of lysenin into oligomers
cannot be precluded, since fetidins and eiseniapore, other
E. foetida proteins, were shown to oligomerize during inter-
action with sphingomyelin-containing membranes [33,43,44].
It is possible that accumulation of sphingomyelin in distinct
membrane microdomains such as sphingolipid/cholesterol-rich
rafts [45,46] can render the microdomains especially suscepti-
ble for lysenin binding. Concentrated lysenin^sphingomyelin
complexes within microdomains may evoke a local damage of
the plasma membrane with subsequent cell lysis. From this
point of view, studies of cytolysis induced by lysenin may help
to reveal if alterations of lipid rafts are su⁄cient to induce cell
death. There are several ways by which lysenin/sphingomyelin
complexes can promote membrane leakage, one of them re-
lated to destabilization of the bilayer due to a local altering of
membrane curvature. This mode of action was described for
pro-apoptotic protein tBid in mitochondrial membrane [47].
One might imagine that after the plasma membrane permea-
bilization, lysenin gets access to a mitochondrial pool of
sphingomyelin and the cytotoxicity of the protein is aug-
mented.
Owing to the cytolytic property of lysenin, the protein was
applied for selection of CHO mutant cells with de¢ciency in
sphingolipid biosynthesis that rendered the cells resistant to
lysenin [48,49]. On the other hand, the lysenin cytotoxicity
limits the application of the protein as a probe for tracing
sphingomyelin in living cells. Thus far, lysenin was used for
sphingomyelin detection in ¢xed cells such as oligodendro-
cytes and ¢broblasts of Niemann^Pick patients. This kind of
studies can be extended for ultrastructural analysis of sphin-
gomyelin topography in cell membranes, similarly to a proce-
dure employed for visualization of cholesterol molecules [50].
The use of sublethal lysenin doses can help to circumvent the
problem of its cytotoxicity. It seems, however, that modi¢ca-
tion of the protein, which will eliminate its lytic activity while
preserving sphingomyelin recognition can provide a lysenin
derivative useful for in vivo studies. A preparation of perfrin-
golysin O derivative is a good example of such an approach
Fig. 2. Lysenin speci¢city. Lipids (4 pmol) spotted onto nitrocellu-
lose were probed with His-tagged recombinant lysenin (2 Wg/ml) fol-
lowed by rabbit anti-His tag and anti-rabbit peroxidase antibodies.
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[51]. Lysenin devoid of its toxic property can be applied for
confocal microscopy analysis of sphingomyelin pools and
their dynamics upon triggering of the sphingomyelin cycle.
Taking into account an accumulation of sphingomyelin in
lipid rafts of the plasma membrane, labeled lysenin can be
used to pursue behavior of rafts and these receptors, which
are thought to transiently associate with rafts for signal gen-
eration. Particularly attractive are novel microscopic ap-
proaches developed to reveal native structure of lipid rafts,
including £uorescence resonance energy transfer microscopy.
4. Lysenin, a puzzling component of defense mechanisms in
earthworm E. foetida
Speci¢c interaction of lysenin with sphingomyelin predis-
poses this protein as a tool for exploring sphingomyelin dis-
tribution and turnover under physiological and pathological
conditions in mammalian cells. Surprisingly, the physiological
function of lysenin in E. foetida is less clear. Lysenin is pro-
duced in large chlorogocytes and large coelomocytes and se-
creted into coelomic £uid of the earthworm [52]. Aside from
lysenin, the coelomic £uid contains a wide spectrum of other
bioactive peptides involved in innate protective pathways [53^
55]. Lytic activity of lysenin and other lytic components of the
coelomic £uid are believed to be an essential mechanism of
defense. However, infectious microbes (bacteria, fungi), ac-
cessing the coelomic cavity after mechanical damages of the
body wall, do not possess sphingomyelin required for the lytic
activity of lysenin. Instead, bacteriostatic properties of fetidins
were attributed to its peroxidase activity [33]. The presence of
peroxidase signature in lysenin suggests a similar antibacterial
activity of the protein.
Taking into account the sphingomyelin-binding ability of
lysenin it was suggested that the protein might contribute to
protection against predator vertebrates, when secreted
through the dorsal pores of the earthworm. Lysenin may
also serve as a defense substance for protection of the earth-
worm sperm, lacking sphingomyelin and discharged under
in£uence of some stimuli, against soil insects, some of which
possess sphingomyelin [42].
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